SIRT6 and osteosarcoma: SIRT6-positivity had a 6.797 fold greater risk of death of osteosarcoma patients (95% CI, 2.129–21.702) and had a 6.516 fold greater risk of relapse of tumor or death of patients (95% CI, 2.234–19.001) (Table 3).